{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:57:02Z","timestamp":1781614622402,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of sentinel lymph node biopsy (SLNB) using blue dye-only in patients who underwent neoadjuvant chemotherapy (NACT) and the axillary recurrence rate in these patients. Additionally, we sought to investigate the impact of this approach on disease-free survival (DFS) and overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who underwent SLNB with blue dye only after receiving NACT for breast cancer between 2013 and 2021 were retrospectively evaluated. The study included patients with invasive breast cancer who were clinically node-negative (cN0) or node-positive (cN1) at admission, received systemic NACT, and converted to clinically node-negative (ycN0) status at restaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 185 patients were included in this study; 68 patients with cN0 tumors remained ycN0 after NACT, and 117 patients with cN1 tumors regressed to ycN0 after NACT. The median age of patients was 44 (IQR 38\u201354) years. Our SLN identification rate was 91% in patients who were cN0 and 88% in those who were cN1 at admission. Overall, SLN was not identified in 20 patients (10.8%). The median follow-up was 59 (IQR, 45\u201381) months. There were 8 (4.3%) locoregional recurrences (6 breast\/chest wall recurrences and 2 axillary recurrences) and 19 (10.3%) distant recurrences. There was no statistically significant difference between the cN0 and cN1 groups regarding locoregional or distant recurrences. No significant differences were observed between the cN0 and cN1 groups in terms of recurrence, DFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.673), or OS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.610).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Sentinel lymph node biopsy using blue dye only after neoadjuvant chemotherapy demonstrated acceptable identification rates and low axillary recurrence in this cohort. However, this approach should not be regarded as standard practice in patients with initially node-positive breast cancer. These findings may reflect feasibility in selected settings with limited resources or where dual-tracer mapping or targeted axillary dissection is not available. Further prospective studies with standardized axillary marking and longer follow-up are needed to confirm these outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-025-04082-9","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T11:56:18Z","timestamp":1762775778000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sentinel lymph node biopsy with blue dye after neoadjuvant chemotherapy in initially node negative and positive breast cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Muhammer","family":"Ergen\u00e7","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Akmercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla Semiha","family":"\u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Bu\u011fdayc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerrin","family":"\u00d6zgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedat","family":"Bayo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahad\u0131r","family":"G\u00fcll\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00dcmit","family":"U\u011furlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"4","key":"4082_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol"},{"issue":"11","key":"4082_CR2","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(11):4515\u201322. https:\/\/doi.org\/10.1245\/s10434-020-08650-z.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"4082_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/s1470-2045(13)70166-9.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4082_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10549-022-06707-z","volume":"196","author":"M Chen","year":"2022","unstructured":"Chen M, Li S, Huang M, Guo J, Huang X, Guo W, et al. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy. Breast Cancer Res Treat. 2022;196(2):267\u201377. https:\/\/doi.org\/10.1007\/s10549-022-06707-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"4082_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2015.63","volume":"12","author":"TA King","year":"2015","unstructured":"King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12(6):335\u201343. https:\/\/doi.org\/10.1038\/nrclinonc.2015.63.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"4082_CR6","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of f axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"J Clin Oncol"},{"issue":"14","key":"4082_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA"},{"issue":"36","key":"4082_CR8","doi-asserted-by":"publisher","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","volume":"23","author":"BT Hennessy","year":"2005","unstructured":"Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005;23(36):9304\u201311. https:\/\/doi.org\/10.1200\/JCO.2005.02.5023.","journal-title":"J Clin Oncol"},{"key":"4082_CR9","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.2147\/cmar.S244806","volume":"12","author":"J Yang","year":"2020","unstructured":"Yang J, Xu L, Liu P, Du Z, Chen J, Liang F, et al. Accuracy of sentinel lymph node biopsy in breast cancer: pitfalls in the application of single tracers. Cancer Manag Res. 2020;12:3045\u201351. https:\/\/doi.org\/10.2147\/cmar.S244806.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"4082_CR10","doi-asserted-by":"publisher","DOI":"10.1590\/acb360608","volume":"36","author":"HM Resende","year":"2021","unstructured":"Resende HM, Lichtenfels M, Soares IC, Ren\u00f3 A, Cunha AP, Falc\u00e3o PG, et al. Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence. Acta Cir Bras. 2021;36(6):e360608. https:\/\/doi.org\/10.1590\/acb360608.","journal-title":"Acta Cir Bras"},{"issue":"4","key":"4082_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21393","volume":"67","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290\u2013303. https:\/\/doi.org\/10.3322\/caac.21393.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"4082_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4082_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-023-07041-8","volume":"201","author":"MU Ugurlu","year":"2023","unstructured":"Ugurlu MU, Bugdayci O, Akmercan A, Kaya H, Akin Telli T, Akoglu H, et al. Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: should we rely on breast MRI to preserve the nipple? Breast Cancer Res Treat. 2023;201(3):417\u201324. https:\/\/doi.org\/10.1007\/s10549-023-07041-8.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4082_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9618","key":"4082_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/s0140-6736(08)60348-7","volume":"371","author":"SM Bentzen","year":"2008","unstructured":"Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098\u2013107. https:\/\/doi.org\/10.1016\/s0140-6736(08)60348-7.","journal-title":"Lancet"},{"issue":"3, Supplement","key":"4082_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.ijrobp.2022.07.2320","volume":"114","author":"FA Vicini","year":"2022","unstructured":"Vicini FA, Winter K, Freedman GM, Arthur DW, Hayman JA, Rosenstein BS, et al. NRG RTOG 1005: a phase III trial of hypo fractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2022;114(3, Supplement):S1. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.2320.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4082_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5578\/turkjsurg.4815","volume":"36","author":"A Sezer","year":"2020","unstructured":"Sezer A, Cicin \u0130, Karadeniz \u00c7akmak G, \u00d6zkan G\u00fcrdal S, Ba\u015faran G, Oyan B, et al. Turkish national consensus on breast cancer management during temporary state of emergency due to COVID-19 outbreak. Turk J Surg. 2020;36(2):147\u201363. https:\/\/doi.org\/10.5578\/turkjsurg.4815.","journal-title":"Turk J Surg"},{"issue":"13","key":"4082_CR18","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1245\/s10434-019-07809-7","volume":"26","author":"D Morency","year":"2019","unstructured":"Morency D, Dumitra S, Parvez E, Martel K, Basik M, Robidoux A, et al. Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC study. Ann Surg Oncol. 2019;26(13):4337\u201345. https:\/\/doi.org\/10.1245\/s10434-019-07809-7.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"4082_CR19","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.3390\/curroncol30030235","volume":"30","author":"O Lovrics","year":"2023","unstructured":"Lovrics O, Tao B, Parvez E. Safety and accuracy of Sentinel lymph node biopsy alone in clinically node-positive patients undergoing upfront surgery for invasive breast cancer: a systematic review. Curr Oncol. 2023;30(3):3102\u201310. https:\/\/doi.org\/10.3390\/curroncol30030235.","journal-title":"Curr Oncol"},{"issue":"4","key":"4082_CR20","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ejso.2014.10.066","volume":"41","author":"K Kida","year":"2015","unstructured":"Kida K, Ishikawa T, Yamada A, Shimizu D, Tanabe M, Sasaki T, et al. A prospective feasibility study of Sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer. Eur J Surg Oncol. 2015;41(4):566\u201370. https:\/\/doi.org\/10.1016\/j.ejso.2014.10.066.","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"4082_CR21","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1200\/jco.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2005;23(12):2694\u2013702. https:\/\/doi.org\/10.1200\/jco.2005.05.188.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4082_CR22","doi-asserted-by":"publisher","first-page":"107967","DOI":"10.1016\/j.ejso.2024.107967","volume":"50","author":"FP Cavalcante","year":"2024","unstructured":"Cavalcante FP, Zerwes FP, Souza ABA, Ziegelmann PK, Alcantara R, Cardoso A, et al. The use of blue dye alone for Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initially node-positive breast cancer. Eur J Surg Oncol. 2024;50(3):107967. https:\/\/doi.org\/10.1016\/j.ejso.2024.107967.","journal-title":"Eur J Surg Oncol"},{"key":"4082_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.breast.2021.07.015","volume":"59","author":"S Cao","year":"2021","unstructured":"Cao S, Liu X, Cui J, Liu X, Zhong J, Yang Z, et al. Feasibility and reliability of Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: an up-to-date meta-analysis of 3,578 patients. Breast. 2021;59:256\u201369. https:\/\/doi.org\/10.1016\/j.breast.2021.07.015.","journal-title":"Breast"},{"issue":"3","key":"4082_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, Steccanella F, Vento AR, Intra M, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol. 2016;42(3):361\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.11.019.","journal-title":"Eur J Surg Oncol"},{"key":"4082_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.breast.2022.12.010","volume":"67","author":"V Galimberti","year":"2023","unstructured":"Galimberti V, Ribeiro Fontana SK, Vicini E, Morigi C, Sargenti M, Corso G, et al. This house believes that: sentinel node biopsy alone is better than TAD after NACT for cN\u2009+\u2009patients. Breast. 2023;67:21\u20135. https:\/\/doi.org\/10.1016\/j.breast.2022.12.010.","journal-title":"Breast"},{"issue":"18","key":"4082_CR26","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1016\/j.ejca.2009.08.001","volume":"45","author":"CH van Deurzen","year":"2009","unstructured":"van Deurzen CH, Vriens BE, Tjan-Heijnen VC, van der Wall E, Albregts M, van Hilligersberg R, et al. Accuracy of Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45(18):3124\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2009.08.001.","journal-title":"Eur J Cancer"},{"issue":"4","key":"4082_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.clbc.2016.02.009","volume":"16","author":"K Enokido","year":"2016","unstructured":"Enokido K, Watanabe C, Nakamura S, Ogiya A, Osako T, Akiyama F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of cytology-proven lymph node-positive breast cancer. Clin Breast Cancer. 2016;16(4):299\u2013304. https:\/\/doi.org\/10.1016\/j.clbc.2016.02.009.","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"4082_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","volume":"212","author":"H El Hage Chehade","year":"2016","unstructured":"El Hage Chehade H, Headon H, El Tokhy O, Heeney J, Kasem A, Mokbel K. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969\u201381. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.07.018.","journal-title":"Am J Surg"},{"issue":"9","key":"4082_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162605","volume":"11","author":"C Geng","year":"2016","unstructured":"Geng C, Chen X, Pan X, Li J. The feasibility and accuracy of Sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. PLoS ONE. 2016;11(9):e0162605. https:\/\/doi.org\/10.1371\/journal.pone.0162605.","journal-title":"PLoS ONE"},{"key":"4082_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205034","author":"P Liu","year":"2022","unstructured":"Liu P, Tan J, Song Y, Huang K, Zhang Q, Xie H. The application of magnetic nanoparticles for Sentinel lymph node detection in clinically node-Negative breast cancer patients: a systemic review and meta-analysis. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14205034.","journal-title":"Cancers (Basel)"},{"key":"4082_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.803804","volume":"12","author":"Y Jin","year":"2022","unstructured":"Jin Y, Yuan L, Zhang Y, Tang P, Yang Y, Fan L, et al. A prospective self-controlled study of indocyanine Green, radioisotope, and methylene blue for combined imaging of axillary sentinel lymph nodes in breast cancer. Front Oncol. 2022;12:803804. https:\/\/doi.org\/10.3389\/fonc.2022.803804.","journal-title":"Front Oncol"},{"issue":"9","key":"4082_CR32","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1245\/s10434-023-13722-x","volume":"30","author":"N Mirzaei","year":"2023","unstructured":"Mirzaei N, W\u00e4rnberg F, Zaar P, Leonhardt H, Olofsson Bagge R. Ultra-low dose of superparamagnetic iron oxide nanoparticles for Sentinel lymph node detection in patients with breast cancer. Ann Surg Oncol. 2023;30(9):5685\u20139. https:\/\/doi.org\/10.1245\/s10434-023-13722-x.","journal-title":"Ann Surg Oncol"},{"key":"4082_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59122077","author":"S Subramonian","year":"2023","unstructured":"Subramonian S, Chopra S, Vidya R. New alternative techniques for sentinel lymph node biopsy. Medicina (B Aires). 2023. https:\/\/doi.org\/10.3390\/medicina59122077.","journal-title":"Medicina (B Aires)"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04082-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04082-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:16:36Z","timestamp":1781612196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04082-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4082"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04082-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. This study was approved by the Marmara University School of Medicine Clinical Research Ethics Committee (Number: 09.2023.1070). Written informed consent was obtained from all patients before performing surgical procedures. The Ethics Committee granted a full waiver of informed consent for reviewing the patient chart and data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"422"}}